News | August 21, 2012

Zoll, Inovise Medical Enter Partnership to Enhance Wearable Defibrillator

August 21, 2012 — Zoll Medical Corp. announced it entered into an agreement to license Inovise Medical Inc.’s ambulatory Audicor technology as part of the advanced patient diagnostics in the LifeVest Wearable Defibrillator.

According to the American Heart Association, an estimated 83 million Americans are currently living with cardiovascular disease (CVD). CVD is responsible for one-third of all deaths annually, or more 2,200 deaths per day, in the United States. The risk of sudden cardiac death is the highest in the days and weeks following an acute cardiac event and during the period of medical therapy optimization, such as adjusting a pharmacologic regimen to treat heart failure.

The LifeVest Wearable Defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing medical condition and until their permanent risk of SCA is established. The LifeVest protects patients during this time of highest risk while they are being optimized on medical therapy. A patient’s condition can improve from the benefits of medical therapy, including meaningful improvement in ejection fraction.

With the addition of the advanced diagnostic features from Inovise, LifeVest will be able to expand the suite of clinically meaningful patient information available to physicians and clinicians to support clinical decisions. In addition to ambulatory monitoring of ECG (electrocardiography), Inovise Medical’s Audicor technology analyzes heart sounds (acoustic cardiography) to provide more diagnostic capabilities and aid in assessing acute and chronic cardiac function for conditions such as heart failure and related co-morbidities.

“The integration of the advanced diagnostic technologies from Inovise with the LifeVest platform further emphasizes our ongoing commitment to providing physicians and clinicians with clinically meaningful tools to improve patient management and outcomes,” said Marshal Linder, president of Zoll.

Peter Bauer, president of Inovise Medical, added, “Inovise’s Audicor technology was developed through years of focused clinical research and algorithm development. We are pleased that, in conjunction with the success of Zoll’s LifeVest product line, physicians and clinicians will have access to our advanced diagnostics to monitor patients during the most vulnerable stages of their cardiac recovery. Inovise is proud to provide the benefits of our ambulatory diagnostic technology to the life-saving therapy of the LifeVest.”

For more information:,

Related Content

A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

Feature | Implantable Cardioverter Defibrillator (ICD) | May 24, 2019 | Dave Fornell, Editor
This is a brief overview of updates on...
Emblem Subcutaneous ICD Safe and Effective for Majority of Patients
News | Implantable Cardioverter Defibrillator (ICD) | May 13, 2019
May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of t
Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Overlay Init